Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolphin Phase II Study of Durvalumab Plus Concurrent Radiation in Advanced Localized NSCLC
jRCT2080224763Phase 2Completed
- Sponsor
- Motoko Tachihara (Coordinating Investigator)
- Start
- Jul 2019
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Motoko Tachihara (Coordinating Investigator). Started Jul 2019; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224763.